ARCTURUS THERAPEUTICS HOLDIN (ARCT)

Notable Friday Option Activity: FTDR, FND, ARCT

Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Arcturus Therapeutics Holdings Becomes Oversold (ARCT)

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

Commit To Buy Arcturus Therapeutics Holdings At $17.50, Earn 28.5% Annualized Using Options

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

/PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and self-amplifying messenger RNA (sa-mRNA) pioneer Arcturus Therapeutics (Nasdaq: ARCT)...

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

Approval underscores CSL and Arcturus Therapeutics' commitment to delivering disruptive technologies to combat COVID-19 and other respiratory viral diseases to...

Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q2 2024

ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Arcturus Therapeutics (NASDAQ:ARCT) just reported results for the second quarte...

Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress

Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference

Arcturus Therapeutics Holdings Enters Oversold Territory (ARCT)

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024

Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs

Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference

Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

/PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announce Nature Communications has...

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences